Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Hadaschik

Showing results (201-210 of 231) with videos related to

Pageof 24
Sort By:
Pathology Oncology Research : POR|August 6, 2020
Prevalence of APC and PTEN Alterations in Urachal CancerNikolett Nagy, Henning Reis, Boris Hadaschik, et al.
European Urology|May 15, 2024
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE TrialAgne Krilaviciute, Rudolf Kaaks, Petra Seibold, et al.
European Urology Oncology|October 8, 2023
Digital Rectal Examination Is Not a Useful Screening Test for Prostate CancerAgne Krilaviciute, Nikolaus Becker, Jale Lakes, et al.
Clinical Genitourinary Cancer|October 22, 2016
The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among CliniciansThomas Martini, Christian Gilfrich, Roman Mayr, et al.
Journal of Behavioral Medicine|March 5, 2025
Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trialValentin H Meissner, Andreas Dinkel, Martina Kron, et al.
Cancer Medicine|January 21, 2023
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomasMelinda Varadi, Nikolett Nagy, Henning Reis, et al.
The Lancet. Oncology|July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective studyAndrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 6, 2025
The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate CancerGernot Ortner, Xenia Hoderlein, Francesco Barbato, et al.
European Urology Oncology|July 10, 2025
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening TrialPeter Albers, Agne Krilaviciute, Petra Seibold, et al.
Annals of Surgical Oncology|August 29, 2014
Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?Marianne Schmid, Michael Rink, Miriam Traumann, et al.
Pageof 24

Showing results (201-210 of 231) with videos related to

Sort By:
Pageof 24
Pathology Oncology Research : POR|August 6, 2020
Prevalence of APC and PTEN Alterations in Urachal CancerNikolett Nagy, Henning Reis, Boris Hadaschik, et al.
European Urology|May 15, 2024
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE TrialAgne Krilaviciute, Rudolf Kaaks, Petra Seibold, et al.
European Urology Oncology|October 8, 2023
Digital Rectal Examination Is Not a Useful Screening Test for Prostate CancerAgne Krilaviciute, Nikolaus Becker, Jale Lakes, et al.
Clinical Genitourinary Cancer|October 22, 2016
The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among CliniciansThomas Martini, Christian Gilfrich, Roman Mayr, et al.
Journal of Behavioral Medicine|March 5, 2025
Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trialValentin H Meissner, Andreas Dinkel, Martina Kron, et al.
Cancer Medicine|January 21, 2023
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomasMelinda Varadi, Nikolett Nagy, Henning Reis, et al.
The Lancet. Oncology|July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective studyAndrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 6, 2025
The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate CancerGernot Ortner, Xenia Hoderlein, Francesco Barbato, et al.
European Urology Oncology|July 10, 2025
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening TrialPeter Albers, Agne Krilaviciute, Petra Seibold, et al.
Annals of Surgical Oncology|August 29, 2014
Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?Marianne Schmid, Michael Rink, Miriam Traumann, et al.
Pageof 24